nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Sorafenib—liver cancer	0.558	1	CbGbCtD
Raltegravir—UGT1A1—Glucuronidation—UGDH—liver cancer	0.00885	0.0587	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR4—liver cancer	0.00872	0.0578	CbGpPWpGaD
Raltegravir—UGT1A1—Glucuronidation—UGDH—liver cancer	0.00718	0.0476	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCR4—liver cancer	0.00698	0.0463	CbGpPWpGaD
Raltegravir—UGT1A1—Heme degradation—HMOX1—liver cancer	0.006	0.0398	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—GSTA1—liver cancer	0.00476	0.0315	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00349	0.0231	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR4—liver cancer	0.00328	0.0218	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00311	0.0206	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCR4—liver cancer	0.00277	0.0184	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—UGDH—liver cancer	0.00271	0.0179	CbGpPWpGaD
Raltegravir—UGT1A1—Porphyrin metabolism—HMOX1—liver cancer	0.00261	0.0173	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.00257	0.017	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.00239	0.0158	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.00233	0.0154	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—GSTM1—liver cancer	0.00232	0.0154	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.0022	0.0146	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—CYP1A1—liver cancer	0.0022	0.0146	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—APC—liver cancer	0.00211	0.014	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.00203	0.0135	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.00198	0.0131	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—DNAJB1—liver cancer	0.0018	0.012	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR4—liver cancer	0.00168	0.0111	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—UGDH—liver cancer	0.00158	0.0105	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA3—liver cancer	0.00155	0.0103	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.0015	0.00994	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA4—liver cancer	0.00142	0.00942	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA2—liver cancer	0.00139	0.00918	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA1—liver cancer	0.00134	0.00886	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—NAT2—liver cancer	0.00132	0.00876	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—F2—liver cancer	0.00131	0.0087	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CHN2—liver cancer	0.00128	0.00846	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IFT88—liver cancer	0.00117	0.00774	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—HPGDS—liver cancer	0.00106	0.007	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.00104	0.00689	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA3—liver cancer	0.00104	0.00687	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—TRIO—liver cancer	0.000988	0.00655	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA4—liver cancer	0.000948	0.00628	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCR4—liver cancer	0.000948	0.00628	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NR1H4—liver cancer	0.000925	0.00613	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA2—liver cancer	0.000924	0.00612	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA3—liver cancer	0.000909	0.00603	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—TRIO—liver cancer	0.000898	0.00595	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTA3—liver cancer	0.000897	0.00594	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA1—liver cancer	0.000891	0.00591	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00088	0.00583	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR4—liver cancer	0.000861	0.0057	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA4—liver cancer	0.000832	0.00551	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTA4—liver cancer	0.00082	0.00544	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA2—liver cancer	0.00081	0.00537	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GGT1—liver cancer	0.000791	0.00524	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NFE2L2—liver cancer	0.000786	0.00521	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA1—liver cancer	0.000782	0.00518	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NAT2—liver cancer	0.000773	0.00512	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—NAT2—liver cancer	0.000762	0.00505	CbGpPWpGaD
Raltegravir—Musculoskeletal pain—Doxorubicin—liver cancer	0.000757	0.0026	CcSEcCtD
Raltegravir—Neck pain—Doxorubicin—liver cancer	0.000757	0.0026	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFA—liver cancer	0.000749	0.00497	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GPX3—liver cancer	0.000749	0.00497	CbGpPWpGaD
Raltegravir—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000748	0.00256	CcSEcCtD
Raltegravir—Hepatocellular injury—Doxorubicin—liver cancer	0.000748	0.00256	CcSEcCtD
Raltegravir—Abnormal dreams—Doxorubicin—liver cancer	0.000739	0.00253	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—SERPINA1—liver cancer	0.000739	0.0049	CbGpPWpGaD
Raltegravir—Eructation—Doxorubicin—liver cancer	0.000734	0.00252	CcSEcCtD
Raltegravir—Rash maculo-papular—Epirubicin—liver cancer	0.000734	0.00252	CcSEcCtD
Raltegravir—Neoplasm—Epirubicin—liver cancer	0.00073	0.00251	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SHC3—liver cancer	0.000716	0.00475	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000711	0.00244	CcSEcCtD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—liver cancer	0.00071	0.00471	CbGpPWpGaD
Raltegravir—Blood urea increased—Doxorubicin—liver cancer	0.000706	0.00242	CcSEcCtD
Raltegravir—Mental disability—Epirubicin—liver cancer	0.000701	0.0024	CcSEcCtD
Raltegravir—Lymphadenopathy—Epirubicin—liver cancer	0.000687	0.00236	CcSEcCtD
Raltegravir—Dyspepsia—Sorafenib—liver cancer	0.000687	0.00235	CcSEcCtD
Raltegravir—Rash maculo-papular—Doxorubicin—liver cancer	0.000679	0.00233	CcSEcCtD
Raltegravir—Decreased appetite—Sorafenib—liver cancer	0.000678	0.00233	CcSEcCtD
Raltegravir—Neoplasm—Doxorubicin—liver cancer	0.000676	0.00232	CcSEcCtD
Raltegravir—Diabetes mellitus—Epirubicin—liver cancer	0.000674	0.00231	CcSEcCtD
Raltegravir—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000674	0.00231	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Sorafenib—liver cancer	0.000673	0.00231	CcSEcCtD
Raltegravir—Fatigue—Sorafenib—liver cancer	0.000672	0.00231	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—F2—liver cancer	0.00067	0.00444	CbGpPWpGaD
Raltegravir—Pain—Sorafenib—liver cancer	0.000667	0.00229	CcSEcCtD
Raltegravir—Constipation—Sorafenib—liver cancer	0.000667	0.00229	CcSEcCtD
Raltegravir—UGT1A1—Phase II conjugation—GSTM1—liver cancer	0.000653	0.00433	CbGpPWpGaD
Raltegravir—Hepatic failure—Epirubicin—liver cancer	0.000653	0.00224	CcSEcCtD
Raltegravir—Mental disability—Doxorubicin—liver cancer	0.000649	0.00222	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—GPX3—liver cancer	0.000648	0.0043	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Sorafenib—liver cancer	0.000638	0.00219	CcSEcCtD
Raltegravir—Lymphadenopathy—Doxorubicin—liver cancer	0.000636	0.00218	CcSEcCtD
Raltegravir—Hot flush—Epirubicin—liver cancer	0.000627	0.00215	CcSEcCtD
Raltegravir—Increased appetite—Epirubicin—liver cancer	0.000624	0.00214	CcSEcCtD
Raltegravir—Diabetes mellitus—Doxorubicin—liver cancer	0.000624	0.00214	CcSEcCtD
Raltegravir—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000624	0.00214	CcSEcCtD
Raltegravir—Menopausal symptoms—Epirubicin—liver cancer	0.000622	0.00213	CcSEcCtD
Raltegravir—Urticaria—Sorafenib—liver cancer	0.00062	0.00213	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—HPGDS—liver cancer	0.000618	0.0041	CbGpPWpGaD
Raltegravir—Abdominal pain—Sorafenib—liver cancer	0.000617	0.00211	CcSEcCtD
Raltegravir—Body temperature increased—Sorafenib—liver cancer	0.000617	0.00211	CcSEcCtD
Raltegravir—Renal impairment—Epirubicin—liver cancer	0.000616	0.00211	CcSEcCtD
Raltegravir—Hepatic failure—Doxorubicin—liver cancer	0.000604	0.00207	CcSEcCtD
Raltegravir—Lethargy—Epirubicin—liver cancer	0.000598	0.00205	CcSEcCtD
Raltegravir—Pain in extremity—Epirubicin—liver cancer	0.000586	0.00201	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000586	0.00388	CbGpPWpGaD
Raltegravir—Hot flush—Doxorubicin—liver cancer	0.00058	0.00199	CcSEcCtD
Raltegravir—Increased appetite—Doxorubicin—liver cancer	0.000578	0.00198	CcSEcCtD
Raltegravir—Migraine—Epirubicin—liver cancer	0.000577	0.00198	CcSEcCtD
Raltegravir—Affect lability—Epirubicin—liver cancer	0.000577	0.00198	CcSEcCtD
Raltegravir—Menopausal symptoms—Doxorubicin—liver cancer	0.000575	0.00197	CcSEcCtD
Raltegravir—Hypersensitivity—Sorafenib—liver cancer	0.000575	0.00197	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000573	0.0038	CbGpPWpGaD
Raltegravir—Renal impairment—Doxorubicin—liver cancer	0.00057	0.00196	CcSEcCtD
Raltegravir—Face oedema—Epirubicin—liver cancer	0.000566	0.00194	CcSEcCtD
Raltegravir—Asthenia—Sorafenib—liver cancer	0.00056	0.00192	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000557	0.00369	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FST—liver cancer	0.000556	0.00368	CbGpPWpGaD
Raltegravir—Mood swings—Epirubicin—liver cancer	0.000556	0.00191	CcSEcCtD
Raltegravir—Lethargy—Doxorubicin—liver cancer	0.000554	0.0019	CcSEcCtD
Raltegravir—Pruritus—Sorafenib—liver cancer	0.000552	0.00189	CcSEcCtD
Raltegravir—Blood creatinine increased—Epirubicin—liver cancer	0.000549	0.00188	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PRKCE—liver cancer	0.000546	0.00362	CbGpPWpGaD
Raltegravir—Pain in extremity—Doxorubicin—liver cancer	0.000543	0.00186	CcSEcCtD
Raltegravir—Dry skin—Epirubicin—liver cancer	0.000538	0.00184	CcSEcCtD
Raltegravir—Abdominal pain upper—Epirubicin—liver cancer	0.000536	0.00184	CcSEcCtD
Raltegravir—Affect lability—Doxorubicin—liver cancer	0.000534	0.00183	CcSEcCtD
Raltegravir—Migraine—Doxorubicin—liver cancer	0.000534	0.00183	CcSEcCtD
Raltegravir—Diarrhoea—Sorafenib—liver cancer	0.000534	0.00183	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TRIO—liver cancer	0.00053	0.00351	CbGpPWpGaD
Raltegravir—Breast disorder—Epirubicin—liver cancer	0.00053	0.00182	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000528	0.00181	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—GGT1—liver cancer	0.000527	0.0035	CbGpPWpGaD
Raltegravir—Nasopharyngitis—Epirubicin—liver cancer	0.000524	0.0018	CcSEcCtD
Raltegravir—Face oedema—Doxorubicin—liver cancer	0.000524	0.0018	CcSEcCtD
Raltegravir—Gastritis—Epirubicin—liver cancer	0.000519	0.00178	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000517	0.00177	CcSEcCtD
Raltegravir—Dizziness—Sorafenib—liver cancer	0.000516	0.00177	CcSEcCtD
Raltegravir—Mood swings—Doxorubicin—liver cancer	0.000514	0.00176	CcSEcCtD
Raltegravir—Abdominal distension—Epirubicin—liver cancer	0.00051	0.00175	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCR4—liver cancer	0.000508	0.00337	CbGpPWpGaD
Raltegravir—Blood creatinine increased—Doxorubicin—liver cancer	0.000508	0.00174	CcSEcCtD
Raltegravir—Influenza—Epirubicin—liver cancer	0.000507	0.00174	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP2E1—liver cancer	0.000504	0.00334	CbGpPWpGaD
Raltegravir—Eosinophilia—Epirubicin—liver cancer	0.000502	0.00172	CcSEcCtD
Raltegravir—Dry skin—Doxorubicin—liver cancer	0.000497	0.00171	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2E1—liver cancer	0.000497	0.00329	CbGpPWpGaD
Raltegravir—Vomiting—Sorafenib—liver cancer	0.000496	0.0017	CcSEcCtD
Raltegravir—Abdominal pain upper—Doxorubicin—liver cancer	0.000496	0.0017	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PRKCE—liver cancer	0.000496	0.00328	CbGpPWpGaD
Raltegravir—Rash—Sorafenib—liver cancer	0.000492	0.00169	CcSEcCtD
Raltegravir—Dermatitis—Sorafenib—liver cancer	0.000491	0.00169	CcSEcCtD
Raltegravir—Breast disorder—Doxorubicin—liver cancer	0.00049	0.00168	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000489	0.00168	CcSEcCtD
Raltegravir—Headache—Sorafenib—liver cancer	0.000489	0.00168	CcSEcCtD
Raltegravir—Bronchitis—Epirubicin—liver cancer	0.000487	0.00167	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—liver cancer	0.000485	0.00166	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CSF2—liver cancer	0.000483	0.0032	CbGpPWpGaD
Raltegravir—Gastritis—Doxorubicin—liver cancer	0.00048	0.00165	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000479	0.00164	CcSEcCtD
Raltegravir—Neutropenia—Epirubicin—liver cancer	0.000474	0.00163	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—liver cancer	0.000474	0.00314	CbGpPWpGaD
Raltegravir—Abdominal distension—Doxorubicin—liver cancer	0.000472	0.00162	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Epirubicin—liver cancer	0.000471	0.00162	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—liver cancer	0.000469	0.00161	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—HMOX1—liver cancer	0.000467	0.0031	CbGpPWpGaD
Raltegravir—Eosinophilia—Doxorubicin—liver cancer	0.000464	0.00159	CcSEcCtD
Raltegravir—Nausea—Sorafenib—liver cancer	0.000463	0.00159	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—GGT1—liver cancer	0.000463	0.00307	CbGpPWpGaD
Raltegravir—Weight increased—Epirubicin—liver cancer	0.000461	0.00158	CcSEcCtD
Raltegravir—Weight decreased—Epirubicin—liver cancer	0.000459	0.00157	CcSEcCtD
Raltegravir—Hyperglycaemia—Epirubicin—liver cancer	0.000457	0.00157	CcSEcCtD
Raltegravir—Infestation NOS—Epirubicin—liver cancer	0.000452	0.00155	CcSEcCtD
Raltegravir—Infestation—Epirubicin—liver cancer	0.000452	0.00155	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—liver cancer	0.000451	0.00155	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000448	0.00154	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000447	0.00296	CbGpPWpGaD
Raltegravir—Renal failure—Epirubicin—liver cancer	0.000444	0.00152	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—liver cancer	0.000443	0.00152	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—liver cancer	0.000439	0.0015	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CSF2—liver cancer	0.000438	0.00291	CbGpPWpGaD
Raltegravir—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000436	0.0015	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—liver cancer	0.000435	0.00289	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HGF—liver cancer	0.000435	0.00289	CbGpPWpGaD
Raltegravir—Haematuria—Epirubicin—liver cancer	0.000431	0.00148	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—liver cancer	0.000427	0.00147	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—liver cancer	0.000427	0.00146	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—liver cancer	0.000426	0.00146	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—liver cancer	0.000424	0.00146	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—liver cancer	0.000423	0.00145	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—liver cancer	0.000418	0.00143	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—liver cancer	0.000418	0.00143	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000417	0.00277	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—liver cancer	0.000415	0.00275	CbGpPWpGaD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000415	0.00142	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—liver cancer	0.000411	0.00141	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—liver cancer	0.00041	0.00141	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—liver cancer	0.00041	0.00272	CbGpPWpGaD
Raltegravir—Hepatitis—Epirubicin—liver cancer	0.000406	0.00139	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—liver cancer	0.000404	0.00138	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ADAM17—liver cancer	0.000402	0.00266	CbGpPWpGaD
Raltegravir—Urinary tract disorder—Epirubicin—liver cancer	0.000401	0.00137	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—liver cancer	0.0004	0.00137	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—liver cancer	0.000399	0.00137	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—liver cancer	0.000399	0.00137	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—liver cancer	0.000398	0.00136	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—liver cancer	0.000395	0.00136	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—liver cancer	0.000394	0.00135	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—liver cancer	0.000391	0.00134	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—liver cancer	0.000384	0.00132	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—liver cancer	0.000382	0.00253	CbGpPWpGaD
Raltegravir—Eye disorder—Epirubicin—liver cancer	0.000379	0.0013	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—F2—liver cancer	0.000379	0.00251	CbGpPWpGaD
Raltegravir—Tinnitus—Epirubicin—liver cancer	0.000378	0.0013	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PSMA4—liver cancer	0.000378	0.0025	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PSMD10—liver cancer	0.000378	0.0025	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—liver cancer	0.000377	0.0025	CbGpPWpGaD
Raltegravir—Cardiac disorder—Epirubicin—liver cancer	0.000377	0.00129	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—liver cancer	0.000375	0.00129	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—liver cancer	0.000374	0.00128	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—liver cancer	0.000371	0.00127	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—liver cancer	0.00037	0.00127	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—liver cancer	0.000369	0.00127	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—liver cancer	0.000368	0.00126	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—liver cancer	0.000368	0.00126	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—liver cancer	0.000366	0.00126	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—liver cancer	0.000366	0.00125	CcSEcCtD
Raltegravir—Chills—Epirubicin—liver cancer	0.000364	0.00125	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—liver cancer	0.000363	0.0024	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP1A1—liver cancer	0.000362	0.0024	CbGpPWpGaD
Raltegravir—Visual impairment—Doxorubicin—liver cancer	0.000362	0.00124	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—liver cancer	0.000359	0.00123	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1A1—liver cancer	0.000357	0.00237	CbGpPWpGaD
Raltegravir—Mental disorder—Epirubicin—liver cancer	0.000355	0.00122	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—liver cancer	0.000355	0.00122	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—liver cancer	0.000353	0.00121	CcSEcCtD
Raltegravir—Erythema—Epirubicin—liver cancer	0.000353	0.00121	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—liver cancer	0.000351	0.0012	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—liver cancer	0.00035	0.0012	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—liver cancer	0.000348	0.00119	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—liver cancer	0.000348	0.00119	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—liver cancer	0.000346	0.00119	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—F2—liver cancer	0.000344	0.00228	CbGpPWpGaD
Raltegravir—Nervousness—Epirubicin—liver cancer	0.000343	0.00118	CcSEcCtD
Raltegravir—Back pain—Epirubicin—liver cancer	0.000342	0.00117	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—liver cancer	0.000341	0.00117	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—liver cancer	0.000339	0.00116	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—liver cancer	0.000338	0.00116	CcSEcCtD
Raltegravir—Chills—Doxorubicin—liver cancer	0.000337	0.00116	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—liver cancer	0.000332	0.00114	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—liver cancer	0.000329	0.00218	CbGpPWpGaD
Raltegravir—Mental disorder—Doxorubicin—liver cancer	0.000329	0.00113	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—liver cancer	0.000328	0.00112	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—liver cancer	0.000327	0.00112	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—liver cancer	0.000327	0.00112	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—liver cancer	0.000326	0.00112	CcSEcCtD
Raltegravir—Agitation—Epirubicin—liver cancer	0.000325	0.00111	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—liver cancer	0.000322	0.0011	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—liver cancer	0.00032	0.0011	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—liver cancer	0.000319	0.00211	CbGpPWpGaD
Raltegravir—Malaise—Epirubicin—liver cancer	0.000318	0.00109	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—liver cancer	0.000317	0.00109	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—liver cancer	0.000317	0.00109	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—liver cancer	0.000316	0.00108	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—liver cancer	0.000312	0.00107	CcSEcCtD
Raltegravir—Cough—Epirubicin—liver cancer	0.000308	0.00106	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—liver cancer	0.000305	0.00105	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—liver cancer	0.000303	0.00104	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—liver cancer	0.000302	0.00104	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—liver cancer	0.000301	0.00103	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—liver cancer	0.000301	0.00103	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—liver cancer	0.000301	0.00103	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—liver cancer	0.0003	0.00103	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—liver cancer	0.0003	0.00103	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000299	0.00102	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—liver cancer	0.000297	0.00102	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—liver cancer	0.000295	0.00101	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—liver cancer	0.000294	0.00101	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—liver cancer	0.000294	0.00101	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PRKCE—liver cancer	0.000293	0.00194	CbGpPWpGaD
Raltegravir—Confusional state—Epirubicin—liver cancer	0.000291	0.000997	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—liver cancer	0.000289	0.00192	CbGpPWpGaD
Raltegravir—Palpitations—Doxorubicin—liver cancer	0.000289	0.00099	CcSEcCtD
Raltegravir—Infection—Epirubicin—liver cancer	0.000286	0.000982	CcSEcCtD
Raltegravir—Cough—Doxorubicin—liver cancer	0.000285	0.000978	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—liver cancer	0.000283	0.00097	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—liver cancer	0.000282	0.000968	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—liver cancer	0.000282	0.000968	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—liver cancer	0.00028	0.00096	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—liver cancer	0.000279	0.000956	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—liver cancer	0.000278	0.000954	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—liver cancer	0.000278	0.000954	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—liver cancer	0.000278	0.000954	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—liver cancer	0.000278	0.00184	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF2—liver cancer	0.000277	0.00184	CbGpPWpGaD
Raltegravir—Anxiety—Doxorubicin—liver cancer	0.000277	0.000951	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000276	0.000948	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—liver cancer	0.000275	0.000943	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—liver cancer	0.000272	0.000933	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—UGDH—liver cancer	0.000271	0.00179	CbGpPWpGaD
Raltegravir—Confusional state—Doxorubicin—liver cancer	0.000269	0.000922	CcSEcCtD
Raltegravir—Infection—Doxorubicin—liver cancer	0.000265	0.000909	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000263	0.000901	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—liver cancer	0.000262	0.000897	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—liver cancer	0.000261	0.000896	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—liver cancer	0.000261	0.000894	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—liver cancer	0.000259	0.000889	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CSF2—liver cancer	0.000259	0.00172	CbGpPWpGaD
Raltegravir—Paraesthesia—Epirubicin—liver cancer	0.000259	0.000888	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—RAF1—liver cancer	0.000258	0.00171	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Doxorubicin—liver cancer	0.000258	0.000884	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—liver cancer	0.000256	0.000879	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—H2AFX—liver cancer	0.000255	0.00169	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—liver cancer	0.000255	0.00169	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—EPT1—liver cancer	0.000255	0.00169	CbGpPWpGaD
Raltegravir—Dyspepsia—Epirubicin—liver cancer	0.000254	0.00087	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—liver cancer	0.000252	0.00167	CbGpPWpGaD
Raltegravir—Decreased appetite—Epirubicin—liver cancer	0.000251	0.000859	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—liver cancer	0.000249	0.000854	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—liver cancer	0.000249	0.000852	CcSEcCtD
Raltegravir—Constipation—Epirubicin—liver cancer	0.000246	0.000845	CcSEcCtD
Raltegravir—Pain—Epirubicin—liver cancer	0.000246	0.000845	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000243	0.000833	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—TAT—liver cancer	0.000241	0.0016	CbGpPWpGaD
Raltegravir—Insomnia—Doxorubicin—liver cancer	0.000241	0.000827	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—liver cancer	0.000239	0.000821	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—liver cancer	0.000238	0.000815	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—liver cancer	0.000237	0.000813	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—liver cancer	0.000236	0.000808	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—liver cancer	0.000235	0.000805	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—liver cancer	0.000232	0.000795	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL2—liver cancer	0.000232	0.00154	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—liver cancer	0.000231	0.00153	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00023	0.00079	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—liver cancer	0.00023	0.000789	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—liver cancer	0.000229	0.000785	CcSEcCtD
Raltegravir—Pain—Doxorubicin—liver cancer	0.000228	0.000782	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—liver cancer	0.000228	0.000782	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—liver cancer	0.000228	0.000782	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—liver cancer	0.000228	0.000782	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—liver cancer	0.00022	0.000754	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—liver cancer	0.000218	0.000748	CcSEcCtD
Raltegravir—Hypersensitivity—Epirubicin—liver cancer	0.000212	0.000728	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—liver cancer	0.000212	0.000727	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KDR—liver cancer	0.000211	0.0014	CbGpPWpGaD
Raltegravir—Body temperature increased—Doxorubicin—liver cancer	0.000211	0.000723	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—liver cancer	0.000211	0.000723	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAPK14—liver cancer	0.00021	0.00139	CbGpPWpGaD
Raltegravir—Asthenia—Epirubicin—liver cancer	0.000207	0.000709	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ESR1—liver cancer	0.000206	0.00136	CbGpPWpGaD
Raltegravir—Pruritus—Epirubicin—liver cancer	0.000204	0.000699	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—F2—liver cancer	0.000203	0.00135	CbGpPWpGaD
Raltegravir—Diarrhoea—Epirubicin—liver cancer	0.000197	0.000676	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—liver cancer	0.000196	0.000674	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—liver cancer	0.000194	0.00129	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APC—liver cancer	0.000194	0.00129	CbGpPWpGaD
Raltegravir—Asthenia—Doxorubicin—liver cancer	0.000191	0.000656	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—liver cancer	0.000191	0.000654	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—liver cancer	0.000189	0.000647	CcSEcCtD
Raltegravir—Vomiting—Epirubicin—liver cancer	0.000183	0.000629	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—BRAF—liver cancer	0.000183	0.00121	CbGpPWpGaD
Raltegravir—Diarrhoea—Doxorubicin—liver cancer	0.000182	0.000626	CcSEcCtD
Raltegravir—Rash—Epirubicin—liver cancer	0.000182	0.000623	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—liver cancer	0.000182	0.000623	CcSEcCtD
Raltegravir—Headache—Epirubicin—liver cancer	0.000181	0.000619	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—liver cancer	0.000177	0.00118	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—liver cancer	0.000176	0.000605	CcSEcCtD
Raltegravir—Nausea—Epirubicin—liver cancer	0.000171	0.000587	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—liver cancer	0.000171	0.00113	CbGpPWpGaD
Raltegravir—Vomiting—Doxorubicin—liver cancer	0.00017	0.000582	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—liver cancer	0.000169	0.00112	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SERPINE1—liver cancer	0.000169	0.00112	CbGpPWpGaD
Raltegravir—Rash—Doxorubicin—liver cancer	0.000168	0.000577	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—liver cancer	0.000168	0.000576	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KRAS—liver cancer	0.000167	0.00111	CbGpPWpGaD
Raltegravir—Headache—Doxorubicin—liver cancer	0.000167	0.000573	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GLUL—liver cancer	0.000164	0.00109	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CPT1B—liver cancer	0.000164	0.00109	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—liver cancer	0.000158	0.000543	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NR1H4—liver cancer	0.000158	0.00105	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA3—liver cancer	0.000155	0.00103	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—liver cancer	0.000154	0.00102	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RAF1—liver cancer	0.000153	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MTOR—liver cancer	0.000149	0.000988	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—liver cancer	0.000149	0.000988	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HRAS—liver cancer	0.000142	0.000943	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA4—liver cancer	0.000142	0.000943	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1B—liver cancer	0.00014	0.000927	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA2—liver cancer	0.000139	0.000919	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—liver cancer	0.000138	0.000917	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP3—liver cancer	0.000137	0.000908	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—liver cancer	0.000137	0.000907	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6—liver cancer	0.000136	0.000903	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA1—liver cancer	0.000134	0.000886	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCND1—liver cancer	0.000133	0.000884	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUN—liver cancer	0.000133	0.000882	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NAT2—liver cancer	0.000132	0.000876	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNB1—liver cancer	0.000132	0.000876	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP9—liver cancer	0.00013	0.000859	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—liver cancer	0.000129	0.000855	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALDOB—liver cancer	0.000127	0.00084	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK8—liver cancer	0.000126	0.000835	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—liver cancer	0.000126	0.000833	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CRABP1—liver cancer	0.000121	0.000801	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFA—liver cancer	0.000116	0.000771	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—liver cancer	0.000115	0.000763	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYC—liver cancer	0.000107	0.000709	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—liver cancer	0.000107	0.000708	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPGDS—liver cancer	0.000106	0.000701	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—liver cancer	9.89e-05	0.000655	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PSMA4—liver cancer	9.42e-05	0.000624	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PSMD10—liver cancer	9.42e-05	0.000624	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GOT2—liver cancer	9.16e-05	0.000607	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—liver cancer	9.08e-05	0.000602	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—liver cancer	8.79e-05	0.000582	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2E1—liver cancer	8.62e-05	0.000571	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—liver cancer	8.4e-05	0.000557	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYCS—liver cancer	8.06e-05	0.000534	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6—liver cancer	8.04e-05	0.000533	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GGT1—liver cancer	7.91e-05	0.000524	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GOT1—liver cancer	7.91e-05	0.000524	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—liver cancer	7.42e-05	0.000492	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—liver cancer	7.11e-05	0.000471	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HMOX1—liver cancer	7.01e-05	0.000464	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—liver cancer	6.53e-05	0.000433	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1A1—liver cancer	6.19e-05	0.00041	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTHFR—liver cancer	5.77e-05	0.000382	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARA—liver cancer	5.66e-05	0.000375	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—liver cancer	4.85e-05	0.000321	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—liver cancer	4.68e-05	0.00031	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—liver cancer	4.26e-05	0.000283	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—liver cancer	4.21e-05	0.000279	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—liver cancer	3.71e-05	0.000246	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—liver cancer	2.26e-05	0.00015	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—liver cancer	1.85e-05	0.000123	CbGpPWpGaD
